105 results about "Female humans" patented technology

Surgical training models of the abdominopelvic region of male and female human patient's bodies to assist in training an operator in microsurgical techniques are disclosed. The surgical training models may be used in training in implantation of implantable medical devices, e.g., in the performance of surgical procedures using particular sling implantation tools to implant a urethral sling to support the urethra or bladder to treat incontinence.

Disclosed is a method for the prevention of and the reduction of risk of breast cancer and ovarian cancer in a female human subject by the administration of selenium (or its salts or derivatives).

Estrogenic compositions comprising nyasol and analogs thereof are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.

Estrogenic extracts of Astragalus membranaceus Fisch. Bge. Var. mongolicus Bge. of the Leguminosae Family are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.

A sexual aid or dildo that is used to collect fluid from a woman's vagina before, during or after a woman's orgasm. A method of using a sexual aid or dildo for tasting fluid from a woman's vagina for increased sexual pleasure. A method of using a dildo for same sex or male to male sexual pleasure.

Provided is a multiple birth prognostic tool that is used to analyze data in order to predict a multiple birth event in a female human patient undergoing an infertility treatment. The MBP prognostic tool may also be used to enhance the accuracy of diagnostic or prognostic tests that predict embryo viability. The MBP prognostic tool of the present invention may be clinic specific or it may be modified to be used in a multi-clinic approach.

The invention discloses a hysteroscopic surgery simulator, which comprises an examining table, a female human model, a uterine cavity resectoscope, a rotation sensor, a displacement sensor, a force feedback touch simulator, data receiving processing equipment, a 3D (three-dimensional) model processing server, a 3D platform system server and display equipment. The hysteroscopic surgery simulator is characterized in that the uterine cavity resectoscope is put in the model; the lower part of the resectoscope body is provided with the displacement sensor and the rotation sensor; the tail end of the resectoscope body is provided with the force feedback touch simulator; the displacement sensor, the rotation sensor and the force feedback touch simulator are respectively and bi-directionally related with the data receiving processing equipment arranged in the examining table. Various 3D stereoscopic models of normal tissues and diseases of a virtual uterine cavity and 3D models for an operation process are stored in the 3D model processing server, and a hysteroscopy and surgery operation interface and entering and playback software are stored, and are output to the display equipment through the 3D platform system server to show vivid virtual 3D images; the hysteroscopic surgery simulator also has a vivid force feedback touch, so that the effects of hysteroscopy, and surgery skill training and assessment can be obviously improved.

The present invention provides improved intravaginal drug delivery devices, i.e., intravaginal rings, useful for the prophylactic administration of an antimicrobial compound, e.g., Dapivirine, to a human. The intravaginal rings of the invention address previous stability issues by utilizing a platinum catalyst (e.g., in the form of a platinum-siloxane complex) for the cross-linking reaction. The vaginal rings surprisingly achieve relatively high and steady release rates in vivo with a matrix ring containing a relatively small loading dose. While the matrix rings of the present invention have in vivo the steady release rates associated with reservoir rings, they are easier and less expensive to manufacture. The present invention also provides methods of blocking DNA polymerization by an HIV reverse transcriptase enzyme, methods of preventing HIV infection in a female human, methods of treating HIV infection in a female human, and methods of preparing platinum-catalyzed intravaginal rings.

The present invention provides methods for boosting mucosal immunity in the female reproductive tract of pre- and post-menopausal women using a TGF-beta inhibitor, a Selective Estrogen Receptor Modulator, and/or a recombinant commensal bacterium that expresses endogenous microbicides into the intestinal tract or reproductive tract of a subject. It also provides methods for boosting innate and adaptive immunity by providing a glucocorticoid. Methods for preventing sexually transmitted infections including HIV infection are also provided.

The subject invention pertains to methods and reagents for the diagnosis of female infertility, prognostic indicators for female infertility, compounds for the treatment of female infertility, compounds and methods for contraception. Methods and compounds are based on the levels of ebaf in endometrial tissue. Methods for diagnosing endometrial receptivity and bleeding function by screening a biological sample such as an endometrial tissue sample, or bodily fluid for the presence of ebaf. A contraceptive compound containing an effective amount of ebaf and a pharmaceutically acceptable carrier. A diagnostic kit for timing contraception containing reagents for screening a sample for the presence of ebaf. A method of treating endometrial irregularities by down-regulating the expression of ebaf.

The invention discloses a charge modified lactoferrin and carrageenin combination medicine which comprises 0.01 part by weight of lactoferrin, 1.5 parts by weight of carrageenin, 5 parts by weight of carbomer, 50 parts by weight of glycerol and 0.1 part by weight of ethylparaben. The combination medicine is one of a gel, a suppository and a dressing. The combination medicine disclosed by the invention can be used for preventing and treating female human papilloma virus infection as well as preventing and treating female gynecological gram-negative bacterium infection.

The breastfeeding shield is configured for comfort and to facilitate the breastfeeding of an infant. The shield is formed of a soft thermoplastic elastomeric, e.g., silicone rubber or the like, and has a major portion closely conforming to the major contours of the female human breast. The major portion is relatively thin, the portion covering the areola being relatively thick and the nipple portion having an intermediate thickness. The hollow nipple includes reinforcing and spacing ribs therein to preclude contact with the natural nipple due to suction and resulting blockage of milk flow. One embodiment is configured for use by full term infants, and another embodiment has a smaller nipple extension for use by premature infants. Different sizes may be provided to suit the nursing mother. The shield is removably secured to the breast by disposable or reusable low-stick adhesive materials.

The herbal women's health formula includes a large variety of herbs that are useful in substantially reducing, if not altogether eliminating, a wide range of symptoms specifically related to women.

A method and device to predict ovulation in a female human by measuring changes in the concentration of a number of ions in eccrine sweat is disclosed. The concentration, or changes in concentration, of one or more ions are determined throughout the day and analyzed against predetermined patterns in order to predict ovulation one to five days in advance. This permits the user to more accurately determine commencement of the fertile phase, which for female humans is generally considered to be about four days prior to ovulation to one day after ovulation. The concentration of the ions measured include sodium (Na+), potassium (K+), ammonium (NH₄+), calcium (Ca₂+), chloride (Cl−) and nitrate (NO₃−). To further increase the accuracy of the reading, a large number of readings can be obtained throughout a day and statistically analyzed to determine the change over time. In addition, the concentration of two or more ions can be obtained to increase accuracy. Ratiometric measurements between two or more ions can be determined to increase accuracy and account for ion accumulation on the skin. Ratiometric measurements between ammonium (NH₄+) and calcium (Ca₂+) have been found to provide more distinct patterns because the concentration of these two ions change in opposite directions during the relevant period preceding ovulation.

Caucasian males, but not females, presenting with statistically significant increases of L162V allelic SNP of the PPARα gene, relative to that of wild-type homozygotes, have an increased likelihood of increased regional adiposity (subcutaneous fat) and BMI, and are more likely to develop diseases associated with such changes, such as type 2 diabetes and metabolic syndrome.